Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia

被引:201
作者
Warkentin, Theodore E.
Sheppard, Jo-Ann I.
Sigouin, Christopher S.
KohImann, Thomas
Eichler, Petra
Greinacher, Andreas
机构
[1] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
[3] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Greifswald, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Dept Transfus Med & Immunol, Greifswald, Germany
关键词
D O I
10.1182/blood-2005-11-012450
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenla (HIT) is caused by antibodies against a "self" protein-platelet factor 4-bound to heparin. We observed an overrepresentation of the female gender in 290 patients who developed HIT after cardiac or orthopedic surgery compared with the representation found in national databases (study 1). Therefore, we investigated gender imbalance in HIT by logistic regression analysis of a randomized controlled trial of unfractionated heparin (UFH) and lowmolecular-weight heparin (LMWH) (study 2), and we analyzed individual patient data from 7 prospective studies comparing HIT frequency between UFH and LMWH, evaluating effects of gender, heparin (UFH vs LMWH), and patient type (surgical vs medical) (study 3). All 3 studies showed female overrepresentation, which for study 3 was a common odds ratio (OR) of 2.37 (95% confidence interval [95% CI], 1.37-4.09; P = .0015). Study 3 also showed an interaction between gender, heparin, and patient type. Although UFH was more likely than LMWH to cause HIT (P < .0001), this effect was predominantly seen in women compared with men (common OR, 9.22 vs 1.83; P = .020) and in surgical patients compared with medical patients (common OR, 13.93 vs 1.75; P = .005). We conclude that females are at greater risk for HIT and that using LMWH to prevent HIT may have greatest absolute benefit in females undergoing surgical thromboprophylaxis.
引用
收藏
页码:2937 / 2941
页数:5
相关论文
共 46 条
[11]   Antiphospholipid syndrome [J].
Gezer, S .
DM DISEASE-A-MONTH, 2003, 49 (12) :696-741
[12]   The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study [J].
Girolami, B ;
Prandoni, P ;
Stefani, PM ;
Tanduo, C ;
Sabbion, P ;
Eichler, P ;
Ramon, R ;
Baggio, G ;
Fabris, F ;
Girolami, A .
BLOOD, 2003, 101 (08) :2955-2959
[13]   Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia [J].
Greinacher, A ;
Eichler, P ;
Lietz, T ;
Warkentin, TE .
BLOOD, 2005, 106 (08) :2921-2922
[14]   Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis [J].
Greinacher, A ;
Farner, B ;
Kroll, H ;
Kohlmann, T ;
Warkentin, TE ;
Eichler, P .
THROMBOSIS AND HAEMOSTASIS, 2005, 94 (01) :132-135
[15]   HEPARIN-ASSOCIATED THROMBOCYTOPENIA - NO ASSOCIATION OF IMMUNE-RESPONSE WITH HLA [J].
GREINACHER, A ;
MUELLERECKHARDT, G .
VOX SANGUINIS, 1993, 65 (02) :151-153
[16]  
GREINACHER A, 1994, THROMB HAEMOSTASIS, V71, P247
[17]   The homozygous FcγRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin platelet factor 4 complexes [J].
Gruel, Y ;
Pouplard, C ;
Lasne, D ;
Magdelaine-Beuzelin, C ;
Charroing, C ;
Watier, H .
BLOOD, 2004, 104 (09) :2791-2793
[18]   Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin [J].
Harbrecht, U ;
Bastians, B ;
Kredteck, A ;
Hanfland, P ;
Klockgether, T ;
Pohl, C .
NEUROLOGY, 2004, 62 (04) :657-659
[19]  
KELTON JG, 1988, BLOOD, V72, P925
[20]  
Lee DH, 2004, HEPARIN INDUCED THRO, P107